Qiagen stock backs EUR 46.50 EQT offer pre-market
Published on 10/23/2026 at 08:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEQT takeover offer announced
- QIAGEN and EQT Private Equity announced a EUR 46.50-per-share cash takeover offer on October 21, 2026.
- The transaction is expected to close in mid-2027, subject to shareholder and regulatory conditions.
- Qiagen stock trades pre-market at EUR 44.80 at 8:07 a.m. CEST at Lang & Schwarz on October 23, 2026.
QIAGEN N.V. and EQT Private Equity announced an agreement on October 21, 2026, under which an EQT-linked bidder will offer EUR 46.50 in cash for each QIAGEN share. The transaction is described in the Business Wire release reproduced by MarketScreener. At 8:07 a.m. CEST on October 23, 2026, the stock was EUR 44.80 at Lang & Schwarz.
Takeover terms and conditions
QIAGEN’s Supervisory Board and Managing Board approved the business combination agreement and agreed to unanimously recommend acceptance of the offer. The transaction is subject to a minimum acceptance threshold of 50% of the outstanding share capital plus one share, approval of specified shareholder resolutions and customary merger-control and foreign-investment clearances. Closing is currently expected in mid-2027, according to the release carried by MarketScreener.
Pre-market indication
The Lang & Schwarz indication is the latest euro price ahead of the Xetra open. The real-time quote of Qiagen stock is updated continuously.
QIAGEN’s business
QIAGEN develops and sells sample-preparation, assay, bioinformatics and automation solutions that help customers extract, analyze and interpret molecular information from biological samples in life-science research and molecular diagnostics, as described on its Investor Relations page. The company serves research and healthcare customers worldwide. Market context: Market report AEX.
